Product
Zibotentan
Aliases
Zibotentan + placebo (placebo matching dapagliflozin tablet)
5 clinical trials
5 indications
Indication
CirrhosisIndication
Healthy Female ParticipantsIndication
chronic kidney diseaseIndication
Chronic Kidney DiseaseIndication
Microvascular anginaClinical trial
A Multicentre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Combination Compared to Zibotentan Monotherapy, Zibotentan/Dapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants With CirrhosisStatus: Recruiting, Estimated PCD: 2025-01-17
Clinical trial
An Open-Label, Single-Sequence Study to Assess the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Ethinyl Estradiol and Levonorgestrel in Healthy Female Participants of Non-Child-Bearing PotentialStatus: Completed, Estimated PCD: 2023-01-10
Clinical trial
A Phase 2b Multicentre, Randomised, Double-Blind, Active-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate (eGFR) ≥ 20 mL/Min/1.73 m^2Status: Completed, Estimated PCD: 2023-06-01
Clinical trial
A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria: a Randomized Double Blind Cross-Over TrialStatus: , Estimated PCD: 2024-04-01
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Cross-over Trial of Zibotentan in Microvascular AnginaStatus: Completed, Estimated PCD: 2023-06-08